| Name | Title | Contact Details |
|---|---|---|
Tim Evans |
Senior Director of Research and Development | Profile |
Dawn Penner |
Vice President Talent Acquisition and Total Rewards | Profile |
Elizabeth Jensen |
Senior Director - Human Resources | Profile |
Coralea Cline |
Vice President of Human Resources and Communications | Profile |
Islet Sciences is a clinical stage biotechnology company engaged in the research, development, and commercialization of new medicines and technologies for the treatment and diagnosis of metabolic disease and related indications where there is significant measurable unmet medical need. The rising incidence of obesity is associated with many obesity-related health complications, including cardiovascular disease, diabetes, hyperlipidemia, hypertension, nonalcoholic fatty liver disease/steatohepatitis (NAFLD/NASH). This constellation is also recognized as the metabolic syndrome and is characterized by underlying insulin resistance. These various diseases have interrelated risk factors and markers, such that often treatment of one disease may allow new therapies and opportunities for treatment in one of these related indications. Our focused effort to develop new therapies and related diagnostics for metabolic related diseases establishes us as a recognized leader in a large and growing market.
Seven Bridges is the industry-leading unified bioinformatics solutions company accelerating precision medicine by enabling the understanding of biomedical data. Our platform, analytic tools, and services expertise are driving discovery and drug development at the world`s leading academic, biotechnology, government, hospitals, and pharmaceutical entities. Through our collaboration with the largest genomics projects, we connect the world`s biomedical information to enable the most efficient analysis at scale.
CellzDirect Inc is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Tempest Therapeutics is a development-stage biotechnology company advancing small molecule therapeutics that modulate anti-tumor immunity pathways.
NexImmune is an emerging biopharmaceutical company advancing a new generation of immunotherapies based on our proprietary AIM™ technology.